← Human Trials & Peer-Reviewed Studies
Subendometrial microvascularization and uterine artery blood flow in IUD-induced side effects (levonorgestrel intrauterine system and copper intrauterine device).
Plain-language guide to PMID 18847582 (2008): clinical trial of Copper (Supplement) in 27 patients.
Key Facts
- PMID
- 18847582
- Journal
- Contraception
- Year
- 2008
- Study type
- Clinical Trial
- Authors
- Jiménez MF et al. (5 authors)
- DOI
- 10.1016/j.contraception.2008.06.013
What This Study Did, in Plain Language
What Was Tested
Researchers studied Copper (Supplement) in this clinical trial publication.
The aim of the study was to quantify the subendometrial microvascularization and uterine artery blood flow in IUD-induced side effects using power Doppler analysis as well as pulsatility index (PI) and resistance index (RI) in the exact midluteal phase 3 months after IUD insertion.
Why It Was Studied
A better understanding of the uterine and endometrial vascularization in intrauterine device (IUD)-induced side effects is clearly of paramount importance in terms of both physiological and pathophysiological changes and may permit assessment for future therapeutic treatments.
There were 27 patients using the levonorgestrel-releasing intrauterine system and 25 patients using TCu 380A.
Who Took Part
According to the abstract, 27 patients were involved.
By PubMed's age tags, the people studied were adults, women only.
How the Study Was Run
This study has a prospective clinical trial design.
What Was Measured
A better understanding of the uterine and endometrial vascularization in intrauterine device (IUD)-induced side effects is clearly of paramount importance in terms of both physiological and pathophysiological changes and may permit assessment for future therapeutic treatments.
The subject headings attached to it are Amenorrhea, Arteries, Dysmenorrhea, Hemorheology, Intrauterine Devices, Copper, Intrauterine Devices, Medicated and Menorrhagia.
What This Means in Plain Language
This is a clinical trial of Copper (Supplement) in 27 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2008 (Contraception), a journal based in United States.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.